PyramIDH

A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)

Arms / Cohorts

Experimental:Ivosidenib for High Risk MDS

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Experimental:Azacitidine for High Risk MDS

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Experimental:Ivosidenib for Low Risk MDS

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Experimental:Azacitidine for Low Risk MDS

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.